Your session is about to expire
← Back to Search
Enzyme Inhibitor
PCNA Inhibitor AOH1996 for Cancer
Phase 1
Waitlist Available
Led By Vincent Chung, MD
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
No Placebo-Only Group
Summary
This trial tests AOH1996, a drug that may stop cancer cell growth by blocking essential enzymes. It targets patients with solid tumors that haven't responded to standard treatments.
Eligible Conditions
- Refractory Malignant Solid Tumor
- Osteosarcoma
- Leiomyosarcoma
- Ovarian Cancer
- Pancreatic Cancer
- Soft tissue sarcoma
- Non-Small Cell Lung Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Dose limiting toxicities
Incidence of adverse events (AEs)
Secondary study objectives
Overall survival
Progression-free survival
Response rate
+1 moreOther study objectives
Levels of plasma gammaH2AX
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment (PCNA inhibitor AOH1996)Experimental Treatment1 Intervention
Patients receive PCNA inhibitor AOH1996 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Find a Location
Who is running the clinical trial?
City of Hope Medical CenterLead Sponsor
602 Previous Clinical Trials
1,923,526 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,924 Previous Clinical Trials
41,017,897 Total Patients Enrolled
Vincent Chung, MDPrincipal InvestigatorCity of Hope Medical Center
5 Previous Clinical Trials
171 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are taking warfarin (a blood thinner medication).You are taking dietary or herbal supplements.You are currently participating in or have recently used any other experimental treatments or medications.You have difficulty taking medication by mouth, such as swallowing pills or experiencing ongoing nausea or vomiting.You are expected to live for more than 3 months.You have a type of cancer that has not responded to regular treatments, or you have chosen not to receive standard treatments.You are currently taking other medications or undergoing other treatments that may interfere with the study.
Research Study Groups:
This trial has the following groups:- Group 1: Treatment (PCNA inhibitor AOH1996)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Solid Tumors Patient Testimony for trial: Trial Name: NCT05227326 — Phase 1
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger